Anyone following OPT (CIR) in Hotcopper now?, page-31

Taken from an article late last year - just to recap on OPT (previously Circadian) huge potential......

Circadian is testing OPT-302 as a combination therapy. In July, Circadian started a Phase I study of OPT-302, in conjunction with Novartis’ treatment Lucentis. This follows pre-clinical studies that showed that combining OPT-302 with the Bayer treatment Eylea improved patient outcomes versus using Eylea alone. While sales of Lucentis and Eylea generate billions of dollars in sales each year (Eylea’s sales in 2014 were US$1.7 billion), the drugs need to be injected every four to eight weeks, and more than half of the patients receiving these drugs do not achieve significant vision gain.

There is a huge market for VEGF-A inhibitors such as Lucentis, Eylea and Avastin: the latter, the first targeted anti-angiogenesis therapy to become a drug, achieved the fastest sales growth of any drug, racing to US$10 billion global sales in its first five years, to 2009. But Circadian’s edge is that OPT-302 also inhibits both VEGF-C and VEGF-D, and can thus be put to work with a VEGF-A inhibitor, for a complete blockage. That is what has the biotech grapevine excited: there are no VEGF-C and VEGF-D inhibitors currently on the market.